Myriad Genetics, Inc. (NASDAQ: MYGN) is 11.39% higher on its value in year-to-date trading and has touched a low of $13.82 and a high of $24.21 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The MYGN stock was last observed hovering at around $21.53 in the last trading session, with the day’s loss setting it -0.21%.
Currently trading at $21.32, the stock is -5.64% and -0.62% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.59 million and changing -0.98% at the moment leaves the stock 8.99% off its SMA200. MYGN registered -6.65% loss for a year compared to 6-month gain of 33.25%. The firm has a 50-day simple moving average (SMA 50) of $2.56 and a 200-day simple moving average (SMA200) of -$9.77.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 0.05% loss in the last 1 month and extending the period to 3 months gives it a 11.92%, and is -6.53% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.98% over the week and 5.32% over the month.
Myriad Genetics, Inc. (MYGN) has around 2700 employees, a market worth around $1.92B and $753.20M in sales. Fwd P/E is 82.26. Profit margin for the company is -34.96%. Distance from 52-week low is 54.27% and -11.94% from its 52-week high. The company has generated returns on investments over the last 12 months (-28.65%).
Myriad Genetics, Inc. quarterly earnings per share for the current quarter are estimated at -$0.1 with sales reaching $193.26M over the same period.The EPS is expected to grow by 108.64% this year, but quarterly earnings will post 9.80% year-over-year. Quarterly sales are estimated to grow 6.70% in year-over-year returns.
288 institutions hold shares in Myriad Genetics, Inc. (MYGN), with institutional investors hold 104.37% of the company’s shares. The shares outstanding are 89.90M, and float is at 86.16M with Short Float at 4.64%. Institutions hold 102.16% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 14.1 million shares valued at $326.94 million. The investor’s holdings represent 17.23% of the MYGN Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 9.15 million shares valued at $212.15 million to account for 11.18% of the shares outstanding. The other top investors are Camber Capital Management LP which holds 6.63 million shares representing 8.10% and valued at over $153.8 million, while Wellington Management Group, LLP holds 7.02% of the shares totaling 5.74 million with a market value of $133.17 million.
Myriad Genetics, Inc. (MYGN) Insider Activity
The most recent transaction is an insider sale by Riggsbee Richard Bryan, the company’s Chief Financial Officer. SEC filings show that Riggsbee Richard Bryan sold 30,000 shares of the company’s common stock on Dec 01 ’23 at a price of $19.09 per share for a total of $0.57 million. Following the sale, the insider now owns 0.29 million shares.
Myriad Genetics, Inc. disclosed in a document filed with the SEC on Nov 01 ’23 that Riggsbee Richard Bryan (Chief Financial Officer) sold a total of 30,000 shares of the company’s common stock. The trade occurred on Nov 01 ’23 and was made at $15.69 per share for $0.47 million. Following the transaction, the insider now directly holds 0.32 million shares of the MYGN stock.
Still, SEC filings show that on Jun 02 ’23, SPIEGELMAN DANIEL K (Director) disposed off 8,638 shares at an average price of $23.01 for $0.2 million. The insider now directly holds 40,493 shares of Myriad Genetics, Inc. (MYGN).
